Sarah K. Madden
Sarah K. Madden has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. Schofield
Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK
3 shared publications - Louise Jane Walport
Protein-Protein Interaction Laboratory, The Francis Crick Institute, London, UK
3 shared publications - Richard J. Hopkinson
Institute for Structural and Chemical Biology and School of Chemistry, University of Leicester, Lancaster Road, Leicester LE1 7RH, UK
3 shared publications - Akane Kawamura
Chemistry - School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU, U.K.
2 shared publications - David Tannahill
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, United Kingdom
2 shared publications - Jody M. Mason
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science Institute for Molecular Bioscience The University of Queensland Brisbane Queensland Australia
2 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 65 (6) , 670-677
Dissecting the Binding Interactions of the Chromatin Remodeler SMARCA4 with G-Quadruplex DNA
DNA G-quadruplexes (G4s) are key structural features in chromatin that are important to genome function. G4s have an apparent capacity to recruit a wide variety of proteins, including chromatin remodelers, yet the molecular basis and biophysical principles governing these interactions remain poorly understood. Here, we sought to build insights into the interactions of chromatin remodeler SMARCA4 with G4s using a biophysical approach. We found that SMARCA4 selectively recognizes the G4 structure over duplex and single-stranded DNA. SMARCA4 binds a wide range of G4s with different topologies and loop lengths with similar low nanomolar affinities. SMARCA4 was also observed to have a longer residency time on the G4 structure compared to that of other known protein-DNA interactions. We also found that the D1 (DExx-c) helicase domain of SMARCA4, which is important for tethering SMARCA4 to chromatinized DNA, was the predominant binding domain for G4 recognition. Our findings reveal new insights into how G4s interact with proteins, which may have important implications for understanding G4-mediated genome mechanisms.
- 27 February 2026
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 65 (6) , 670-677
Open AccessDissecting the Binding Interactions of the Chromatin Remodeler SMARCA4 with G-Quadruplex DNA
DNA G-quadruplexes (G4s) are key structural features in chromatin that are important to genome function. G4s have an apparent capacity to recruit a wide variety of proteins, including chromatin remodelers, yet the molecular basis and biophysical principles governing these interactions remain poorly understood. Here, we sought to build insights into the interactions of chromatin remodeler SMARCA4 with G4s using a biophysical approach. We found that SMARCA4 selectively recognizes the G4 structure over duplex and single-stranded DNA. SMARCA4 binds a wide range of G4s with different topologies and loop lengths with similar low nanomolar affinities. SMARCA4 was also observed to have a longer residency time on the G4 structure compared to that of other known protein-DNA interactions. We also found that the D1 (DExx-c) helicase domain of SMARCA4, which is important for tethering SMARCA4 to chromatinized DNA, was the predominant binding domain for G4 recognition. Our findings reveal new insights into how G4s interact with proteins, which may have important implications for understanding G4-mediated genome mechanisms.
- 5 June 2025
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 68 (9) , e1778-e1779
Robotic Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Low-Grade Pseudomyxoma Peritonei and as a Risk Reduction Procedure
An abstract is unavailable. This article is available as a PDF only.
- 5 June 2025
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 68 (9) , e1778-e1779
Robotic Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Low-Grade Pseudomyxoma Peritonei and as a Risk Reduction Procedure
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 2 December 2023
- Published by Wiley in Journal of Peptide Science
- Vol. 30 (5) , e3557
A library‐derived peptide inhibitor of the BZLF1 transcription factor
Transcription factor dysregulation is associated with many diseases, including cancer. Peptide‐based molecules are increasingly recognised as important modulators of difficult intracellular protein–protein interaction targets, with peptide library screening consequently proven to be a viable strategy in developing inhibitors against a wide range of transcription factors (TFs). However, current strategies simply select the highest affinity of binding to a target TF rather than the ability to inhibit TF function. Here, we utilise our Transcription Block Survival (TBS) screening platform to enable high‐throughput identification of peptides that inhibit TFs from binding to cognate DNA sites, hence inhibiting functionality. In this study, we explore whether the TBS can be expanded to derive a potent and functional peptide inhibitor of the BZLF1 transcription factor. The library‐derived peptide, AcidicW, is shown to form a more stable dimer with BZLF1 than the BZLF1 homodimer, with a thermal denaturation temperature exceeding 80°C. AcidicW can also functionally inhibit the BZLF1:TRE DNA interaction with high potency and an IC50 of 612 nM.
- 2 December 2023
- Published by Wiley in Journal of Peptide Science
- Vol. 30 (5) , e3557
Open AccessA library‐derived peptide inhibitor of the BZLF1 transcription factor
Transcription factor dysregulation is associated with many diseases, including cancer. Peptide‐based molecules are increasingly recognised as important modulators of difficult intracellular protein–protein interaction targets, with peptide library screening consequently proven to be a viable strategy in developing inhibitors against a wide range of transcription factors (TFs). However, current strategies simply select the highest affinity of binding to a target TF rather than the ability to inhibit TF function. Here, we utilise our Transcription Block Survival (TBS) screening platform to enable high‐throughput identification of peptides that inhibit TFs from binding to cognate DNA sites, hence inhibiting functionality. In this study, we explore whether the TBS can be expanded to derive a potent and functional peptide inhibitor of the BZLF1 transcription factor. The library‐derived peptide, AcidicW, is shown to form a more stable dimer with BZLF1 than the BZLF1 homodimer, with a thermal denaturation temperature exceeding 80°C. AcidicW can also functionally inhibit the BZLF1:TRE DNA interaction with high potency and an IC50 of 612 nM.
- Open Access
- 9 December 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (50) , 23096-23103
DNA G-Quadruplex Recognition In Vitro and in Live Cells by a Structure-Specific Nanobody
G-quadruplexes (G4s) are four-stranded DNA secondary structures that occur in the human genome and play key roles in transcription, replication, and genome stability. G4-specific molecular probes are of vital importance to elucidate the structure and function of G4s. The scFv antibody BG4 has been a widely used G4 probe but has various limitations, including relatively poor in vitro expression and the inability to be expressed intracellularly to interrogate G4s in live cells. To address these considerations, we describe herein the development of SG4, a camelid heavy-chain-only derived nanobody that was selected against the human Myc DNA G4 structure. SG4 exhibits low nanomolar affinity for a wide range of folded G4 structures in vitro. We employed AlphaFold combined with molecular dynamics simulations to construct a molecular model for the G4-nanobody interaction. The structural model accurately explains the role of key amino acids and Kd measurements of SG4 mutants, including arginine-to-alanine point mutations that dramatically diminish G4 binding affinity. Importantly, predicted amino acid-G4 interactions were subsequently confirmed experimentally by biophysical measurements. We demonstrate that the nanobody can be expressed intracellularly and used to image endogenous G4 structures in live cells. We also use the SG4 protein to positionally map G4s in situ and also on fixed chromatin. SG4 is a valuable, new tool for G4 detection and mapping in cells.
- 9 December 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (50) , 23096-23103
Open AccessDNA G-Quadruplex Recognition In Vitro and in Live Cells by a Structure-Specific Nanobody
G-quadruplexes (G4s) are four-stranded DNA secondary structures that occur in the human genome and play key roles in transcription, replication, and genome stability. G4-specific molecular probes are of vital importance to elucidate the structure and function of G4s. The scFv antibody BG4 has been a widely used G4 probe but has various limitations, including relatively poor in vitro expression and the inability to be expressed intracellularly to interrogate G4s in live cells. To address these considerations, we describe herein the development of SG4, a camelid heavy-chain-only derived nanobody that was selected against the human Myc DNA G4 structure. SG4 exhibits low nanomolar affinity for a wide range of folded G4 structures in vitro. We employed AlphaFold combined with molecular dynamics simulations to construct a molecular model for the G4-nanobody interaction. The structural model accurately explains the role of key amino acids and Kd measurements of SG4 mutants, including arginine-to-alanine point mutations that dramatically diminish G4 binding affinity. Importantly, predicted amino acid-G4 interactions were subsequently confirmed experimentally by biophysical measurements. We demonstrate that the nanobody can be expressed intracellularly and used to image endogenous G4 structures in live cells. We also use the SG4 protein to positionally map G4s in situ and also on fixed chromatin. SG4 is a valuable, new tool for G4 detection and mapping in cells.
- Top Cited PapersOpen Access
- 4 January 2021
- Published by Springer Nature in Molecular Cancer
- Vol. 20 (1) , 1-18
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
C-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.
- 4 January 2021
- Published by Springer Nature in Molecular Cancer
- Vol. 20 (1) , 1-18
Top Cited PapersOpen AccessTaking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
C-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.
- 4 December 2020
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 13 (2) , 95-98
Peptide Library Screening As a Tool to Derive Potent Therapeutics: Current Approaches and Future Strategies
- 4 December 2020
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 13 (2) , 95-98
Peptide Library Screening As a Tool to Derive Potent Therapeutics: Current Approaches and Future Strategies
- 1 July 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1868 (7) , 140405
Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery
- 1 July 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1868 (7) , 140405
Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery
- 11 February 2019
- Published by Wiley in Protein Science
- Vol. 28 (4) , 738-745
Exploring new strategies for grafting binding peptides onto protein loops using a consensus‐designed tetratricopeptide repeat scaffold
Peptide display approaches, in which peptide epitopes of known binding activities are grafted onto stable protein scaffolds, have been developed to constrain the peptide in its bioactive conformation and to enhance its stability. However, peptide grafting can be a lengthy process requiring extensive computational modeling and/or optimisation by directed evolution techniques. In this study, we show that ultra‐stable consensus‐designed tetratricopeptide repeat (CTPR) proteins are amenable to the grafting of peptides that bind the Kelch‐like ECH‐associated protein 1 (Keap1) onto the loop between adjacent repeats. We explore simple strategies to optimize the grafting process and show that modest improvements in Keap1‐binding affinity can be obtained by changing the composition of the linker sequence flanking either side of the binding peptide.
- 11 February 2019
- Published by Wiley in Protein Science
- Vol. 28 (4) , 738-745
Exploring new strategies for grafting binding peptides onto protein loops using a consensus‐designed tetratricopeptide repeat scaffold
Peptide display approaches, in which peptide epitopes of known binding activities are grafted onto stable protein scaffolds, have been developed to constrain the peptide in its bioactive conformation and to enhance its stability. However, peptide grafting can be a lengthy process requiring extensive computational modeling and/or optimisation by directed evolution techniques. In this study, we show that ultra‐stable consensus‐designed tetratricopeptide repeat (CTPR) proteins are amenable to the grafting of peptides that bind the Kelch‐like ECH‐associated protein 1 (Keap1) onto the loop between adjacent repeats. We explore simple strategies to optimize the grafting process and show that modest improvements in Keap1‐binding affinity can be obtained by changing the composition of the linker sequence flanking either side of the binding peptide.
- Open Access
- 6 April 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 14773
Highly selective inhibition of histone demethylases by de novo macrocyclic peptides
The JmjC histone demethylases (KDMs) are linked to tumour cell proliferation and are current cancer targets; however, very few highly selective inhibitors for these are available. Here we report cyclic peptide inhibitors of the KDM4A-C with selectivity over other KDMs/2OG oxygenases, including closely related KDM4D/E isoforms. Crystal structures and biochemical analyses of one of the inhibitors (CP2) with KDM4A reveals that CP2 binds differently to, but competes with, histone substrates in the active site. Substitution of the active site binding arginine of CP2 to N-ɛ-trimethyl-lysine or methylated arginine results in cyclic peptide substrates, indicating that KDM4s may act on non-histone substrates. Targeted modifications to CP2 based on crystallographic and mass spectrometry analyses results in variants with greater proteolytic robustness. Peptide dosing in cells manifests KDM4A target stabilization. Although further development is required to optimize cellular activity, the results reveal the feasibility of highly selective non-metal chelating, substrate-competitive inhibitors of the JmjC KDMs.
- 6 April 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 14773
Open AccessHighly selective inhibition of histone demethylases by de novo macrocyclic peptides
The JmjC histone demethylases (KDMs) are linked to tumour cell proliferation and are current cancer targets; however, very few highly selective inhibitors for these are available. Here we report cyclic peptide inhibitors of the KDM4A-C with selectivity over other KDMs/2OG oxygenases, including closely related KDM4D/E isoforms. Crystal structures and biochemical analyses of one of the inhibitors (CP2) with KDM4A reveals that CP2 binds differently to, but competes with, histone substrates in the active site. Substitution of the active site binding arginine of CP2 to N-ɛ-trimethyl-lysine or methylated arginine results in cyclic peptide substrates, indicating that KDM4s may act on non-histone substrates. Targeted modifications to CP2 based on crystallographic and mass spectrometry analyses results in variants with greater proteolytic robustness. Peptide dosing in cells manifests KDM4A target stabilization. Although further development is required to optimize cellular activity, the results reveal the feasibility of highly selective non-metal chelating, substrate-competitive inhibitors of the JmjC KDMs.
- Open Access
- 2 December 2014
- Published by Taylor & Francis in Epigenetics
- Vol. 9 (12) , 1596-1603
Studies on the catalytic domains of multiple JmjC oxygenases using peptide substrates
The JmjC-domain-containing 2-oxoglutarate-dependent oxygenases catalyze protein hydroxylation and Nϵ-methyllysine demethylation via hydroxylation. A subgroup of this family, the JmjC lysine demethylases (JmjC KDMs) are involved in histone modifications at multiple sites. There are conflicting reports as to the substrate selectivity of some JmjC oxygenases with respect to KDM activities. In this study, a panel of modified histone H3 peptides was tested for demethylation against 15 human JmjC-domain-containing proteins. The results largely confirmed known Nϵ-methyllysine substrates. However, the purified KDM4 catalytic domains showed greater substrate promiscuity than previously reported (i.e., KDM4A was observed to catalyze demethylation at H3K27 as well as H3K9/K36). Crystallographic analyses revealed that the Nϵ-methyllysine of an H3K27me3 peptide binds similarly to Nϵ-methyllysines of H3K9me3/H3K36me3 with KDM4A. A subgroup of JmjC proteins known to catalyze hydroxylation did not display demethylation a...
- 2 December 2014
- Published by Taylor & Francis in Epigenetics
- Vol. 9 (12) , 1596-1603
Open AccessStudies on the catalytic domains of multiple JmjC oxygenases using peptide substrates
The JmjC-domain-containing 2-oxoglutarate-dependent oxygenases catalyze protein hydroxylation and Nϵ-methyllysine demethylation via hydroxylation. A subgroup of this family, the JmjC lysine demethylases (JmjC KDMs) are involved in histone modifications at multiple sites. There are conflicting reports as to the substrate selectivity of some JmjC oxygenases with respect to KDM activities. In this study, a panel of modified histone H3 peptides was tested for demethylation against 15 human JmjC-domain-containing proteins. The results largely confirmed known Nϵ-methyllysine substrates. However, the purified KDM4 catalytic domains showed greater substrate promiscuity than previously reported (i.e., KDM4A was observed to catalyze demethylation at H3K27 as well as H3K9/K36). Crystallographic analyses revealed that the Nϵ-methyllysine of an H3K27me3 peptide binds similarly to Nϵ-methyllysines of H3K9me3/H3K36me3 with KDM4A. A subgroup of JmjC proteins known to catalyze hydroxylation did not display demethylation a...